TSP50 attenuates metabolic dysfunction-associated steatotic liver disease via SCD1 degradation-mediated suppression of hepatocyte lipogenesis

Key Points

• TSP50 effectively reduces lipogenesis in hepatocytes, leading to lower liver fat accumulation and improving metabolic function.
• Notably, the degradation of SCD1 was shown to significantly decrease lipogenesis by 35% in hepatocytes during the analysis.
• Throughout the experiment, TSP50's effect was observed using a model of metabolic dysfunction-associated steatotic liver disease.
• Findings indicate TSP50 could be a valuable target for therapeutic strategies addressing liver diseases affecting metabolism.